Naarmutestin

Naarmutestin, also known as 17β-hydroxy-11β-methyl-5α-pregn-4-en-3-one, is a synthetic anabolic-androgenic steroid (AAS) that was developed in the 1960s. It is a derivative of testosterone, with modifications to its molecular structure to enhance its anabolic properties while reducing its androgenic effects. Naarmutestin is primarily used in the field of veterinary medicine, where it is administered to livestock to promote muscle growth and improve performance. Its use in human athletes is not recommended due to potential health risks, including liver toxicity and suppression of natural hormone production. Naarmutestin is classified as a Schedule III substance in the United States, indicating a potential for abuse and dependence. Its legal status varies by country, with some nations banning its use entirely. The compound is typically administered in the form of tablets or injectable solutions.